Clinical Research, Pharma & Healthcare FinancingAlphyn Doses First Patients in CLEAR-AD1 Phase 2b TrialPR NewswireMay 12, 2025May 13, 2025 by PR NewswireMay 12, 2025May 13, 2025066 Zabalafin Hydrogel first topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection Alphyn GmbH,...
